Open Access
A dose of competition : EU antitrust law in the pharmaceuticals sector
License
Access Rights
Cadmus Permanent Link
Full-text via DOI
ISBN
ISSN
1572-4042
Issue Date
Type of Publication
Keyword(s)
LC Subject Heading
Other Topic(s)
EUI Research Cluster(s)
Initial version
Published version
Succeeding version
Preceding version
Published version part
Earlier different version
Initial format
Author(s)
Citation
TILEC Discussion Paper; DP2015/017; [Florence School of Regulation]; [Energy Union Law]
Cite
HANCHER, Leigh, SAUTER, Wolf, A dose of competition : EU antitrust law in the pharmaceuticals sector, TILEC Discussion Paper, DP2015/017, [Florence School of Regulation], [Energy Union Law] - https://hdl.handle.net/1814/39422
Abstract
In the pharmaceuticals sector there is an inherent tension between intellectual property rights and antitrust. This paper examines this tension over the past 10 years since modernisation of EU competition law. It looks at three types of problems: (i) restrictions on parallel imports; (ii) abuse of administrative procedure; and (iii) pay for delay cases. This overview shows that the European Commission is now especially active in areas (ii) and (iii) and generally relies on a more formalistic approach of finding restrictions by object instead of using economic arguments to demonstrate restrictions by effect. The by object approach is supported by the EU Courts. Also, the molecule (active ingredient) is often regarded as the relevant product market, facilitating a finding of dominance. Some national competition authorities have followed in the footsteps of the Commission but on the whole they are less active, for instance on pay for delay. This may be because the EU Courts have yet to rule on this type of case. For pharmaceutical companies the net result is that they cannot assume their intellectual property rights will stand in the way of a finding of antitrust infringement and their behaviour will be scrutinised closely.